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Development of cardiac hypertrophy and progres-
sion to heart failure entails profound changes in
myocardial metabolism, characterized by a switch
from fatty acid utilization to glycolysis and lipid accu-
mulation. We report that hypoxia-inducible factor
(HIF)1a and PPARg, key mediators of glycolysis
and lipid anabolism, respectively, are jointly upregu-
lated in hypertrophic cardiomyopathy and cooperate
to mediate key changes in cardiac metabolism. In
response topathologic stress,HIF1aactivates glyco-
lytic genes and PPARg, whose product, in turn, acti-
vates fatty acid uptake and glycerolipid biosynthesis
genes. These changes result in increased glycolytic
flux and glucose-to-lipid conversion via the glycerol-
3-phosphate pathway, apoptosis, and contractile
dysfunction. Ventricular deletion of Hif1a in mice
prevents hypertrophy-induced PPARg activation,
the consequent metabolic reprogramming, and
contractile dysfunction.Weproposeamodel inwhich
activation of the HIF1a-PPARg axis by pathologic
stress underlies key changes in cell metabolism that
are characteristic of and contribute to common forms
of heart disease.
INTRODUCTION
Heart failure remains one of the most frequent causes of death in
the industrialized world. It is the final common pathway of many
forms of heart disease induced by a variety of pathological
insults, including hypertension, myocardial infarction, and aortic
stenosis. These stressors, if protracted or severe, lead to
a progressive worsening of cardiac function and ultimately heart
failure (Guzy et al., 2005).
A common feature of pathologic hypertrophy is the reprog-
ramming of cardiac energy metabolism. Fatty acids represent
the predominant fuel for the adult heart under normal physiologic512 Cell Metabolism 9, 512–524, June 3, 2009 ª2009 Elsevier Inc.conditions. However, hypertrophied and failing hearts demon-
strate an increased reliance on glucose while decreasing their
fatty acid utilization (Lehman and Kelly, 2002). This shift in
substrate utilization may be provoked in part by myocardial
hypoxia that develops as a result of a mismatch between
myocardial oxygen demand and supply during stress-induced
hypertrophy (MacLellan and Schneider, 2000). Altered substrate
metabolism may ultimately fail to satisfy the energetic demands
of the heart, contributing to heart failure.
In mammalian cells, decreased oxygen availability stimulates
cells to reprogram their metabolism from a mitochondrial oxida-
tive to a glycolytic form of ATP production. Hypoxia-inducible
factor (HIF), dimers composed of HIF1a, HIF2a, or HIF3a (collec-
tively HIFa) and HIFb/ARNT subunits, plays a key role coordi-
nating this adaptive response. HIFa subunits are constitutively
degraded under normoxia due to prolyl hydroxylase activity,
which marks them for degradation by the von Hippel-Lindau
(VHL) tumor suppressor protein pVHL. Consequently, loss of
pVHL or hypoxia leads to activation of HIF and a number of genes
involved in the regulation of cell metabolism, including glucose
transporters, glycolytic enzymes, and pyruvate dehydrogenase
(PDH) kinase (PDK)1 (DeBerardinis et al., 2008). This serves to
increase intracellular glucose uptake, augment glycolysis, and
shunt pyruvate away from mitochondria. Despite the low
overall percentage of pyruvate available for mitochondrial entry,
cardiac-specific ablation of VHL or HIF1a overexpression in vitro
leads to TAG accumulation, defective mitochondrial biogenesis,
and reduced fatty acid oxidation (Belanger et al., 2007; Lei et al.,
2008; Narravula and Colgan, 2001; Zhang et al., 2007); its molec-
ular and metabolic basis remains incompletely understood.
TAG synthesis requires free fatty acids (FFAs) and the obliga-
tory intermediary glycerol-3-phosphate. Glycerol-3-phosphate
can originate from glycerol through the action of glycerol
kinase. While rates of FFA uptake are increased during cardiac
hypertrophy (Taylor et al., 2001), cardiomyocytes display a low
capacity for glycerol uptake (McGavock et al., 2006). However,
glycerol-3-phosphate can be generated via glycerol-3-phos-
phate dehydrogenase (GPD1), which dehydrogenates dihy-
droxyacetone phosphate (DHAP), an intermediate of glycolysis.
Glycerol-3-phosphate serves then as the substrate for glycerol
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de novo TAG synthesis (Gonzalez-Baro et al., 2007). Genes
encoding GPD1 and GPAT have been identified as direct tran-
scriptional targets for the peroxisome proliferator-activated
receptor g (PPARg), a member of the nuclear-receptor transcrip-
tion factor family (Cao et al., 2006; Patsouris et al., 2004). PPARg
plays an important role in lipid metabolism, promoting FFA
uptake and TAG accumulation in adipose tissue and liver (Spie-
gelman, 1998). Its role in the heart is less clear. Cardiomyocyte-
restricted PPARg knockout mice develop cardiac hypertrophy
but do not reveal changes in lipid metabolism genes (Duan
et al., 2005). In contrast, cardiac PPARg-overexpressing mice
develop dilated cardiomyopathy, display increased FFA uptake,
and accumulate TAG (Son et al., 2007). These observations,
combined with evidence supporting a central role for HIF in
promoting glycolysis, raise the intriguing possibility of a potential
crosstalk of HIF and PPARg transcription factors in the regulation
of glucose and lipid metabolism in the heart.
In the present study, we demonstrate that HIF1a and PPARg
protein expression is upregulated in human and mouse cardiac
hypertrophy. Using cardiac-restricted Hif1a as well as Vhlh
knockout mice, we find that HIF1a directly activates PPARg
transcription and that PPARg is a key downstream effector of
HIF1a-driven TAG accumulation and apoptosis in cardiomyo-
cytes. These results suggest a mechanism for reprogramming
of fuel utilization and TAG accumulation in cardiomyocytes
during cardiac hypertrophy, in which HIF1a induces glycolytic
enzymes and, through PPARg activation, FFA uptake and glyc-
erolipid biosynthesis, resulting in cardiac steatosis. Moreover,
stress-induced HIF1a activation promotes cardiomyocyte
apoptosis in a PPARg-dependent manner and leads to dimin-
ished cardiac function.
RESULTS
Cardiac Hypertrophy Is Associated with Increased
Expression of HIF1a and PPARg
Ventricular biopsies of human and mouse models of pathological
hypertrophy were assessed for HIF1a expression by immuno-
blotting. Compared to control, high HIF1a levels were observed
in hypertrophic cardiomyopathy (HCM) of human samples
(Figure 1A) and in vivo mouse models of HCM corresponding to
aortic stenosis and pressure overload (transaortic constriction
[TAC]) (Figure 1B), defective b-adrenergic signaling (isoproter-
enol [ISO] infusion) (Figures S1A and S1B), and hypertension
(angiotensin 2 overexpression) (Figures S1A and S1B). Treatment
of primary neonatal mouse cardiomyocytes (NMCs) with hyper-
trophy-inducing agents such as ISO, norepinephrine, and phe-
nylepinephrine (PE) likewise resulted in an induction of HIF1a
protein (Figure S1C) and nuclear translocation (Figure S1D,
subpanels c and d, e and f, and g and h, respectively). Intriguingly,
PPARg and the product of the PPARg target gene GPAT
also accumulated in human and mouse TAC-induced HCMs
(Figures 1A and 1B). In contrast, M-Cpt1, a PPARa and PPARb/d
target gene and critical component of mitochondrial fatty acid
transport required for b-oxidation, was downregulated (Figures
1A and 1B). Swimming-induced physiological cardiac hyper-
trophy in the mouse led to the induction of neither HIF1a nor
PPARg (Figure S1E) (Luo et al., 2005). Thus, increased expres-sion of HIF1a and PPARg appears to be a common feature of
pathologic cardiac hypertrophy in vivo.
To extend these findings, expression profiling of a subset of
glycolytic, nuclear receptor, and nuclear receptor target genes
was performed by quantitative real-time PCR (qPCR) on HCMs
of human and TAC-induced mouse hearts. Glycolytic genes
such as glucose transporter 1 (GLUT1), hexokinase 2, muscle
phosphofructokinase, glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH), and PDK, isozyme 4 were upregulated in
diseased human and TAC mouse heart samples (Figures 1C
and 1D). The mRNA levels of PPARa and PPARb/d, two positive
transcriptional regulators of lipid catabolism, were reduced to
various degrees (Figures 1C and 1D). PPARg, a transcriptional
regulator of lipid anabolism, and the PPARg target genes,
GPD1 and GPAT, were also increased (Figures 1C and 1D), in
accord with the immunoblotting data shown above (Figures 1A
and 1B). Hence, induction of HCM in humans and mouse
models is associated with the activation of key transcriptional
regulators of glycolysis and lipid anabolism, HIF1a and PPARg,
respectively.
To investigate a potential link between stress-induced hyper-
trophy and the accumulation of HIF1a and PPARg, mice with
loxP-flanked Hif1a (Hif1a fl/fl) (Ryan et al., 1998; Schipani et al.,
2001) or Vhlh (Vhlh fl/fl) (Haase et al., 2001) alleles were crossed
to myosin light-chain (Mlc)2v-Cre (Chen et al., 1998) transgenic
mice to generate Mlc2v-Cre; Hif1a fl/fl (hereafter referred to as
Hif1a cKO) and Mlc2v-Cre; Vhlh fl/fl (hereafter referred to as
Vhlh cKO) mice. The Mlc2v-Cre transgene induces Cre-medi-
ated recombination specifically in the ventricular cardiomyo-
cytes of the mouse heart (Chen et al., 1998). Deletion of either
Hif1a or Vhlh was confirmed by PCR-mediated detection of the
corresponding recombined alleles (data not shown). Hif1a cKO
mice were viable and phenotypically indistinguishable from
control Hif1a fl/fl mice, consistent with earlier analysis of such
mice (Huang et al., 2004). Vhlh cKO mice did not exhibit any
developmental or postnatal phenotype (data not shown). Around
3–4 months of age, these mice exhibited increased heart size
and concentric ventricular hypertrophy (data not shown), which
further developed at 5–6 months of age into eccentric hyper-
trophy characterized by severe ventricular and atrial hypertrophy
as well as thinning of the ventricular wall and dilation of the
ventricular cavity (Figures S2A–S2C).
Immunoblotting of lysates of ventricles from Vhlh fl/fl, Vhlh
cKO, Hif1a fl/fl, and Hif1a cKO mice revealed a marked accumu-
lation of HIF1a, PPARg, and the PPARg target gene products
FAT/CD36 and GPAT in the Vhlh cKO ventricles, but not in the
ventricles of the other genotypes (Figure 1E). The levels of
PPARa and PPARb/d family members involved in lipid catabo-
lism did not change significantly (Figure 1E). In contrast, PGC-
1a, a transcriptional coactivator important for the expression of
mitochondrial biogenesis and b-oxidation genes, and the mito-
chondrial proteins M-Cpt1, voltage-dependent anion-selective
channel (VDAC), and succinate dehydrogenase complex subunit
A (SDHA) were downregulated in Vhlh cKO ventricles (Figure 1E).
Interestingly, in Hif1a cKO ventricles, PGC-1a, M-Cpt1, VDAC,
and SDHA protein levels were upregulated (Figures 1E). Expres-
sion profiling by qPCR revealed that several glycolytic genes,
PPARg,GPD1, andGPAT, were activated in Vhlh cKO ventricles,
while genes whose products are involved in mitochondrialCell Metabolism 9, 512–524, June 3, 2009 ª2009 Elsevier Inc. 513
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Regulation of Cardiac Metabolism by a HIF1a-PPARg AxisFigure 1. HIF1a Accumulation Correlates with and Promotes Pathological Hypertrophy
(A and B) Human (A) and mouse (B) normal and diseased ventricles were assessed for HIF1a, PPARg, GPAT, and M-Cpt1 protein expression. Cardiac actin and
sarcomeric a-actinin serve as loading controls for the human and mouse sample sets, respectively.
(C and D) Gene expression profiling of hypertrophic and metabolic markers was performed on human (C) and mouse (D) normal and diseased ventricles. All values
were normalized internally to 18S RNA expression and to the normal human and the mouse sham control sets, respectively (*, p < 0.01; **, p < 0.05). Data are
means ± SEM of values from each group.
(E) Ventricular whole-cell lysates of the respective genotypes were probed for protein expression of HIF1a, PPARa, PPARb/d, PPARg, GPAT, PGC-1a, M-Cpt1,
VDAC, SDHA, and FAT/CD36. Sample loading was normalized to sarcomeric a-actinin. Broken lines are used to separate the respective sets. All samples were
run on the same gel.biogenesis and function were decreased (Figure S3A, upper
subpanels). In Hif1a cKO ventricles, glycolytic and PPARg
gene expression was not upregulated, but PPARa and PPARb/d
expression was increased (Figure S3B, upper subpanel). Mito-
chondrial gene expression was generally increased in Hif1a
cKO ventricles (Figure S3B, lower subpanel). Combined, these
changes suggest that Vhlh inactivation mediates reprogramming
of cardiomyocyte metabolism from a mitochondrial to a glyco-
lytic form of energy production. It appears that Hif1a deficiency
inverses this metabolic program. In keeping with this view, mito-
chondrial respiratory function (Figure S4A), mitochondrial DNA514 Cell Metabolism 9, 512–524, June 3, 2009 ª2009 Elsevier Inc.content (Figure S4B), and mitochondrial surface area (Figures
S4C and S4D) were decreased in Vhlh cKO but enhanced in
Hif1a cKO ventricles compared to control ventricles.
PPARg Is a Target Gene of HIF1a in Cardiomyocytes
The coordinate upregulation of HIF1a and PPARg in response to
hypertrophic stimuli or inactivation of Vhlh raised the intriguing
possibility of a dependency of PPARg expression on HIF1a. To
test this, NMCs were treated with PE, an a-adrenergic receptor
agonist, and ISO and assessed for HIF1a, GAPDH, PPARg,
and GPAT mRNA expression. As shown in Figures 2A and
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HIF1a. Infection of these cells with lentiviral short hairpin RNAs
targeting HIF1a mRNA (shHIF1a) reduced HIF1a mRNA expres-
sion and abolished induction of GAPDH, PPARg, and GPAT by
PE and ISO (Figures 2A and S5A, respectively). Downregulation
of PPARg with a corresponding lentiviral shRNA (shPPARg)
blocked selectively the expression of PE- or ISO-induced PPARg
and GPAT, but not of GAPDH (Figures 2A and S5A). In contrast,
ectopic expression of a constitutively active form of HIF1a
that escapes pVHL-mediated degradation through alanine
substitutions at the HIF1a proline hydroxylation sites Pro402
and Pro577 (referred to as HIF1aDPro) (Staller et al., 2003)
induced GAPDH, PPARg, and GPAT in the absence of hypertro-
phic stimuli (Figure 2B). Although overexpression of PPARg was
sufficient to induce expression of GPAT, it had negligible effects
on HIF1a or GAPDH expression (Figure 2B). The efficacy of the
respective lentiviruses is shown in Figures S8A and S8D. These
results indicate that hypertrophy-induced PPARg expression is,
at least in part, HIF1a dependent and that the subsequent induc-
tion of GPAT expression is PPARg dependent.
We next assessed if PPARg is a direct HIF1a target. In silico
analysis revealed a potential hypoxic response element (HRE)
located 1042 bp upstream of the PPARg transcriptional start
site. This HRE is conserved between the mouse and human
PPARg promoter (Figure 2C). Mouse wild-type (WT) promoter
and the corresponding PPARg promoter fragment mutated at
this HRE site were joined to the luciferase reporter gene and
transfected into NMCs. ISO addition or HIF1aDPro coexpression
activated the WT PPARg promoter in a HRE-dependent manner,
as the PPARg-HRE mutant promoter was unresponsive to these
treatments (Figure 2D). Lentiviral expression of shHIF1a but not
of a control nonsilencing (ns) shRNA (nsRNA) completely abol-
ished PE- or ISO-induced PPARg promoter activation (Figures
2D and S5B). Immunoblotting confirmed that HIF1a failed to
accumulate in response to PE or ISO in shHIF1a-infected cells
(data not shown).
Chromatin immunoprecipitation (ChIP) assays on nuclear
extracts of shVHL-infected NMCs using antibodies against
HIF1a showed that HIF1a associated with the HRE in the PPARg
as well as the GAPDH promoters in native chromatin only in
shVHL-infected NMCs (Figure 2E). A similar association between
HIF1a and the PPARg promoter was observed with ISO stimula-
tion (Figure S5C). Thus, PPARg is a HIF1a target gene.
A HIF1a-PPARg sequential transcriptional pathway would be
predicted to induce GPAT promoter activity in a reporter assay
and to promote the interaction of PPARg with the respec-
tive promoters via PPAR response elements (PPREs) upon
HIF1a activation. In silico analysis of the GPAT promoter
revealed a PPRE upstream of the transcriptional start site at
position 1027 bp that is conserved in human and mouse
promoters (Figure 2F). The GPAT WT and PPRE mutant (GPAT
DPPRE) promoters were analyzed in NMCs. Expression of
HIF1aDPro activated the GPAT promoter. The mutant GPAT
DPPRE promoter responded also to HIF1aDPro, but to a lesser
degree (Figure 2G). Expression of PPARg induced GPAT
promoter activity in a PPRE-dependent manner (Figure 2G).
These results suggest that HIF1a activates the GPAT promoter,
at least in part, through a PPARg-dependent mechanism. Addi-
tionally, ChIP assays demonstrated that PPARg associatedwith the predicted PPRE in the GPAT as well as the GPD1
promoters specifically in the presence of lentiviral shVHL or ISO
(Figures 2H and S5D).
Hypertrophic Stimuli Induces Myocardial Steatosis
in a HIF1a-Dependent Manner
PPARg is a potent inducer of TAG synthesis. Based on the
capacity for HIF1a and hypertrophic stimuli to induce PPARg
expression and transcriptional activity, we asked if pathological
stimuli would increase myocardial TAG content in vivo and, if so,
whether this was dependent on HIF1a function. TAC and the
one-kidney-one-clip (1K1C) are two established models of
mouse pathological hypertrophy. Ventricular biopsies of mice
subjected to TAC or 1K1C were assessed for TAG content by
oil red O (ORO) staining. TAG accumulation was observed
specifically in Hif1a fl/fl but not in Hif1a cKO ventricles subjected
to TAC (Figures 3A and 3E) or 1K1C (Figure 3B). Ventricular-
specific Vhlh deficiency caused lipid accumulation (Figures 3C
and 3E), consistent with a previous report (Lei et al., 2008).
Thus, HIF1a is essential for cardiac lipid accumulation in
response to hypertrophic stimuli.
To verify if the HIF1a-dependent TAG accumulation occurred
in a cell-autonomous fashion, Hif1a fl/fl NMCs were cultured in
the presence of ISO or PE and stained for HIF1a, sarcomeric
a-actinin, DAPI, and ORO (Figure S6A). ISO and PE both induced
lipid accumulation inHIF1a fl/fl NMCs (Figures S6A, subpanels i–
l and q–t, respectively, and 3F), but not when HIF1a was ablated
by infection with a Cre-expressing adenoviral vector (Figures
S6A, subpanels m–p and u–x, respectively, and 3F).
Given the HIF1a dependency of lipid accumulation and glycol-
ysis, we determined the impact of hypertrophic agents on the
contribution of glucose-derived carbon to TAG synthesis. Glyc-
erol phosphate dehydrogenases form an important link between
carbohydrate and lipid metabolism (Lewin and Coleman, 2003).
As a result of glucose metabolism, DHAP generated from the
breakdown of fructose-1-6-bisphosphate by aldolase retains
the carbon moiety at position 1 of glucose (C1), which upon
conversion to glycerol-3-phosphate by GPD1 is acylated by
GPAT to culminate in TAG incorporation (Figure S7). Glucose
labeled at C1 would be predicted to incorporate in TAG upon
hypertrophic induction if hypertrophy promoted the preferential
channeling of DHAP toward TAG synthesis and if the glycerol
component of the stored lipids did derive from the glycolytic
cascade (Denton and Halperin, 1968). 14C1-glucose was added
to Hif1a fl/fl NMCs in the presence of PE, and stored TAG was
extracted and analyzed for 14C incorporation (Figure 3F). 14C
incorporation in TAG was observed almost exclusively in hyper-
trophy-induced NMCs and occurred in a HIF1a-dependent
fashion, as evidenced by the observation that deletion of the
HIF1a allele by adenoviral Cre recombinase (Ad-Cre) expression
blocked PE-induced 14C-glucose incorporation into TAG. Ad-Cre
alone did not significantly affect 14C incorporation in TAG
(Figure S6B). Thus, activation of HIF1a in response to hypertro-
phicsignals contributes significantly to the conversion of glucose-
derived carbon to lipid synthesis in NMCs.
HIF1a Coregulates Glycolysis and TAG Synthesis
Fructose-1,6-bisphosphate breakdown by aldolase gives rise to
DHAP and glyceraldehyde-3-phosphate. Generated DHAP canCell Metabolism 9, 512–524, June 3, 2009 ª2009 Elsevier Inc. 515
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(A) NMCs were treated with PE in the presence of shHIF1a or shPPARg and assayed for HIF1a, GAPDH, PPARg, and GPAT expression by qPCR (*, p < 0.01
compared to control, set at 1.0). Data are means ± SEM of values from each group.
(B) NMCs were transfected with HIF1aDPro or PPARg expression vector and assayed for HIF1a, GAPDH, PPARg, and GPAT expression by qPCR. All values
shown are normalized to HIF1a, GAPDH, PPARg, and GPAT levels in mock transfected NMCs. Levels of HIF1a, GAPDH, PPARg, and GPAT expression in
mock transfected NMCs are set at 1.0 (*, p < 0.01). Data are means ± SEM of values from each group.
(C) Sequence analysis of the human and mouse PPARg promoter showing conserved putative HREs (underlined). The core consensus HRE motif is shown in
bold.
(D) PPARg promoter activity in response to HIF1a was determined by transient cotransfection of WT or HRE-mutated PPARg promoters, respectively, fused
to luciferase and with either an empty vector control or the HIF1aDPro expression construct or stimulated with PE in the presence or absence of shHIF1a. All
transfections contained equal amounts of a b-galactosidase expression vector for normalization of luciferase activity (c¸, %, and **, p < 0.01; *, p < 0.05). Data
are means ± SEM of values from each group.516 Cell Metabolism 9, 512–524, June 3, 2009 ª2009 Elsevier Inc.
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GPD1 or converted to glyceraldehyde-3-phosphate and returned
to the glycolytic branch by triosephosphate isomerase (TPI).
Accordingly, the upregulation of GLUT1 and glycolytic enzymes
by HIF1a and consequent increase of FAT/CD36, GPD1, and
GPAT by HIF1a-mediated PPARg expression would ensure
a coordinate engagement of the glycolytic and glycerolipid
biosynthetic branches (Figure S7).
To verify the establishment of such a mode of coregulation in
the context of cardiomyocyte hypertrophy, we first determined
Figure 3. In Vivo Pathological Hypertrophy
and VHL Loss Promote Ventricular Steato-
sis
(A and B) Ventricular cross-sections of Hif1a fl/fl or
Hif1a cKO mice subjected to TAC (A) or 1K1C (B)
were stained for oil red O (red) and counterstained
with hematoxylin (blue).
(C) Cross-sections of Vhlh fl/fl and Vhlh cKO ventri-
cles were stained for oil red O (red) and counter-
stained with hematoxylin (blue).
(D) Quantification of ventricular TAG content of
Vhlh fl/fl, VHL cKO, Hif1a fl/fl, or Hif1a cKO mice.
TAG content was normalized to tissue weight (*,
p < 0.01; **, p < 0.05). Data are means ± SEM of
values from four or five mice.
(E) Hif1a fl/fl NMCs were treated with a solvent
control or PE in the presence of nsRNA, shPPARg,
or Ad-Cre and assessed for TAG accumulation by
oil red O staining and absorbance (510 nm)
measurements of extracted lipids (*, c¸, and &,
p < 0.01). Data are means ± SEM of values from
each group.
(F) 14C1-glucose incorporation in TAG was
assessed in Hif1a fl/fl NMCs in solvent control or
PE-treated cultures in the presence or absence of
Ad-Cre. Normalized levels of 14C1-TAG incorpora-
tion in the respective culture conditions are shown
(*, c¸, and &, p < 0.01; C, solvent control; ISO,
isoproterenol; PE, phenylepinephrine; Ad-C,
control adenovirus; Ad-Cre, Cre recombinase
encoding adenovirus; Rel., relative). Data are
means ± SEM of values from each group.
if PE-mediated hypertrophy had an effect
on glucose and lipid uptake and, if so,
whether these changes could be ascribed
to HIF1a. PE-induced Hif1a fl/fl NMCs
displayed increased levels of glucose
and FFA uptake (Figures 4A and 4B,
respectively). This increase was abol-
ished upon Ad-Cre infection, suggesting that hypertrophy-
induced glucose and lipid uptake occurs in a HIF1a-dependent
fashion. Ad-Cre infection of WT cells had negligible effects on
glucose and FFA uptake compared to mock infected cells (data
not shown). Next, we addressed if the increase in glucose and
lipid uptake in hypertrophy had any bearing on intracellular cardi-
omyocyte TAG content. Indeed, TAG generation in PE-treated
NMCs was achieved only when both glucose and FFAs were
added (Figure 4C), implying a requirement for both glucose and
FFAs for TAG synthesis in response to hypertrophic stimulus.(E) nsRNA control and shVHL-treated NMCs were assessed for interaction of HIF1a at the PPARg promoter by ChIP. DNA from the respective samples were
immunoprecipitated with a HIF1a-specific antibody (IP:HIF1a) or with a control isotype-matched antibody (IP:Ig control). Interaction of HIF1a at the GAPDH
locus, an established HIF1a transcriptional target, served as a positive control for the ChIP.
(F) Sequence analysis of the human and mouse GPAT promoter showing conserved putative PPREs (underlined). The core consensus PPRE motif is shown
in bold.
(G) GPAT promoter activity in response to HIF1a and PPARg was determined by transient cotransfection of WT or PPRE-mutated GPAT promoter, respectively,
fused to luciferase and with either an empty vector control or HIF1aDPro or PPARg expression constructs. All transfections contained equal amounts of
a b-galactosidase expression vector for normalization of luciferase activity (c¸, &, %, and *, p < 0.05; **, p < 0.01). Data are means ± SEM of values from each group.
(H) nsRNA control and shVHL-treated NMCs were assessed for interaction of PPARg at the GPAT promoter by ChIP. DNA from the respective samples were
immunoprecipitated with a PPARg-specific antibody (IP:PPARg) or with a control isotype-matched antibody (IP:Ig control). Interaction of PPARg at the GPD1
locus, an established PPARg transcriptional target, served as a positive control for the ChIP.Cell Metabolism 9, 512–524, June 3, 2009 ª2009 Elsevier Inc. 517
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Regulation of Cardiac Metabolism by a HIF1a-PPARg AxisFigure 4. HIF1a Promotes TAG Synthesis by Coregulating Glycolysis and Glycerolipid Synthesis
(A and B) Hif1a fl/fl NMCs were stimulated with a solvent control (diamond) or PE (square and triangle), mock infected with an empty adenovirus (square) or one
encoding Cre recombinase (triangle), and assessed for glucose (A) and oleate (B) uptake at the respective time points.
(C) Solvent control or PE-stimulated NMCs were cultured in glucose and fatty-acid-free medium containing exogenous glucose and/or oleate and assessed for
intracellular TAG levels by oil red O staining and absorbance (510 nm) measurements of extracted lipids (*, p < 0.01). Data are means ± SEM of values from each
group.
(D and E) NMCs were treated with a solvent control or PE in the presence of nsRNA, shHIF1a, or shPPARg and assayed for GAPDH (*, c¸, and &, p < 0.01) (D) and
GPD1 (*, p < 0.01) (E) enzymatic activity. Data are means ± SEM of values from each group.518 Cell Metabolism 9, 512–524, June 3, 2009 ª2009 Elsevier Inc.
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enzymes at the crossroads of glycolysis and the glycerolipid
biosynthetic pathways, were altered in hypertrophy and if the
observed changes could be ascribed to HIF1a and PPARg.
HIF1a knockdown inhibited both GAPDH and GPD1 enzymatic
activity in NMCs treated with PE, whereas PPARg knockdown
resulted only in a specific decrease in GPD1 activity (Figures
4D and 4E). Consistent with these observations, knockdown of
HIF1a or PPARg reduced also the levels of intracellular TAG
content upon PE addition (Figure 4F). To underscore the require-
ment for a flux through both the glycolytic (via GLUT1 and
GAPDH) and the glycerolipid synthesis (via FAT/CD36 and
GPD1) branches for TAG synthesis, shGLUT1, shGAPDH,
shFAT/CD36, or shGPD1 were added to PE-treated NMCs. Inhi-
bition of either GLUT1 or GAPDH expression led to decreased
intracellular TAG levels, confirming the requirement for glycolytic
metabolites in TAG synthesis. Similarly, inhibition of FAT/CD36
or GPD1 led to decreased TAG accumulation upon PE stimula-
tion (Figure 4F). The efficacy of the respective lentiviral shRNAs
in knocking down endogenous gene expression is shown in
Figures S8C–S8F.
As ventricular TAG accumulation was observed in our
mouse models of pathological hypertrophy, we asked if the
glycolytic and glycerolipid synthesis pathways are also engaged
in vivo and depend on HIF1a. To this end, ventricular biopsies of
sham and TAC-induced Hif1a fl/fl mice were assessed for
GAPDH, GPD1, and GPAT enzymatic activities. TAC induced
a significant rise in the enzymatic activity of the glycolytic enzyme
GAPDH and of the glycerolipid pathway enzymes GPD1 and
GPAT (Figures 4G–4I). The simultaneous increase in enzymatic
activities along the two pathways in TAC-induced hypertrophy
was mimicked byVhlhdeficiency in the absence of a hypertrophic
stimulus (Figures 4G–4I). However, ablation of HIF1a function in
ventricles prevented the activation of GAPDH, GPD1, and
GPAT enzymatic activities in response to TAC (Figures 4G–4I).
In contrast, levels of glucose oxidation, as represented by citrate
synthase activity, was markedly reduced in TAC-induced Hif1a
fl/fl and Vhlh deficiency ventricles compared to TAC-induced
Hif1acKOandVhlhfl/flcontrol ventricles, respectively (Figure 4J).
Bearing in mind the restriction of the cardiac steatosis phenotype
to hearts subjected to hypertrophic stress such as TAC and 1K1C
or the loss of ventricular Vhlh, the data above are consistent with
the notion that hypertrophy-induced HIF1a accumulation
augments TAG synthesis through coregulation of the glycolytic
and glycerolipid biosynthetic branches.
Next we asked whether the accumulation of TAG occurred in
an environment of reduced fatty acid oxidation. As shown in
Figure 4K, expression of HIF1a led to a significant inhibition of
the rate of palmitate oxidation, whereas knockdown of HIF1a
augmented it (Figure 4K). This effect was recapitulated in vivo
using the ‘‘working heart model,’’ insofar as Hif1a-deficient heartsexhibited marginally increased palmitate oxidation concomitant
with a decreased rate of glycolysis (Figures S9F and S9G). Taken
together, these results suggest that HIF1a activation promotes
both the glycolytic and glycerolipid biosynthetic pathways in
hypertrophic hearts at the expense of glucose and fatty acid
oxidation.
HIF1a Activation Induces PPARg-Dependent Apoptosis
in Cardiomyocytes
Cardiomyocyte lipid accumulation is reported to promote lipo-
toxicity and cardiomyocyte apoptosis, leading to cardiac
dysfunction and failure (Lee et al., 2004, 2006; McGavock et al.,
2006). As both Vhlh-deficient and TAC-stimulated ventricles
exhibit increased TAG accumulation, we asked whether these
ventricles are also characterized by increased apoptosis. Indeed,
TUNEL staining of tissue sections of TAC-induced or Vhlh-defi-
cient ventricles revealed increased DNA strand breaks, indicative
of apoptosis (Figures 5A–5C). Counterstaining for sarcomeric
a-actinin demonstrated costaining with TUNEL-positive cells,
implying that the affected cells are NMCs (Figures 5A–5C). There
were little if any TUNEL-positive cells when TAC was applied
to Hif1a cKO mice (Figures 5A and 5B). Immunoblotting of
extracts of ventricles from these genotypes for cleaved caspase
3 confirmed our immunohistochemical data (Figures 5D–5F).
Thus, HIF1a function is critical for the induction of apoptosis
that accompanies hypertrophy.
To determine whether PPARg is a critical downstream effector
of HIF1a-dependent apoptosis in response to hypertrophic
signals, cultured NMCs were infected with lentiviral shHIF1a or
shPPARg followed by treatment with PE. The latter induced
HIF1a accumulation and apoptosis, as evidenced by TUNEL
staining (Figure S10A, subpanels e–h and q–t). Knockdown of
HIF1a by shRNA blocked HIF1a accumulation and cell death
upon PE treatment. Strikingly, depletion of PPARg also inhibited
cardiomyocyte apoptosis but did not prevent accumulation of
HIF1a in the presence of PE (Figure S10A, subpanels m–p and
y–a2). PPARg knockdown also inhibited cell death that occurred
in Vhlh-deficient NMCs. Cell death under these various condi-
tions correlated with increased levels of intracellular TAG, as
assessed by BodiPy staining (Figure S10B). Hence, HIF1a-
induced cardiomyocyte death depends on PPARg.
To further explore the mechanism of PPARg-mediated cell
death, we tested various downstream effectors that have been
previously implicated in induction of apoptosis. The transcrip-
tional activator Oct1/Pou2f1 is an established PPARg target
gene that activates the growth arrest and DNA damage-inducible
45A (GADD45A) gene (Bruemmer et al., 2003; Mueller et al.,
2000), whose product promotes the cleavage and activation of
caspase 3 (Harkin et al., 1999). The increase in cleaved caspase
3 observed upon both TAC and Vhlh loss led us to address if
HIF1a, via PPARg, activated such a pathway in NMCs to promote(F) NMCs were treated with a solvent control or PE in the presence of nsRNA, shHIF1a, shGLUT1, shGAPDH, shPPARg, shCD36, or shGPD1 and assessed for
TAG accumulation by oil red O staining and absorbance (510 nm) measurements of extracted lipids (*, p < 0.01 compared to PE-treated nsRNA controls). Data are
means ± SEM of values from each group.
(G–J) Ventricular lysates of Hif1a fl/fl or Hif1a cKO mice subjected to the sham or TAC protocol and of Vhlh fl/fl or Vhlh cKO mice were assessed for endogenous
GAPDH (G), GPD1 (H), GPAT (I), and citrate synthase (J) enzymatic activity (*, c¸, and #, p < 0.01; **, p < 0.05). Data are means ± SEM of values from four or five
mice.
(K) NMCs were treated with nsRNA, shHIF1a, or HIF1a overexpressing viruses and assessed for palmitate oxidation capacity (* and c¸, p < 0.01; C, solvent control;
PE, phenylepinephrine; Rel., relative). Data are means ± SEM of values from each group.Cell Metabolism 9, 512–524, June 3, 2009 ª2009 Elsevier Inc. 519
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Regulation of Cardiac Metabolism by a HIF1a-PPARg AxisFigure 5. HIF1a Accumulation Correlates with Cardiomyocyte Lipid Accumulation and Apoptosis
(A–C) Cross-sections of Hif1a fl/fl or Hif1a cKO ventricles subjected to the sham (A) or TAC (B) protocol and of Vhlh fl/fl or Vhlh cKO ventricles (C) were assessed
for DNA double-strand breaks by TUNEL and counterstained for sarcomeric a-actinin and DAPI.
(D–F) Whole-cell lysates of Hif1a fl/fl or Hif1a cKO ventricles subjected to the sham (D) or TAC (E) protocol and of Vhlh fl/fl or Vhlh cKO ventricles (F) were assessed
for cleaved caspase 3 levels by immunoblotting. Loading was normalized to sarcomeric a-actinin.
(G–H) NMCs were infected with nsRNA, shHIF1a, or shPPARg or transfected with the HIF1aDPro or PPARg expression vector and assayed for Oct1 (G) or
GADD45A (H) expression by qPCR (*, c¸, and #, p < 0.01). Data are means ± SEM of values from each group.
(I) Oct1 activity in response to HIF1a was determined by transient cotransfection of a synthetic WT or ORE-mutated Oct1 reporter, respectively, fused to lucif-
erase and with either an empty vector control or the HIF1aDPro or PPARg expression construct in the presence or absence of shPPARg. All transfections520 Cell Metabolism 9, 512–524, June 3, 2009 ª2009 Elsevier Inc.
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Regulation of Cardiac Metabolism by a HIF1a-PPARg Axisapoptosis. Overexpression of HIF1a in NMCs led to increased
expression of Oct1 and its target gene GADD45A in a PPARg-
dependent manner (Figures 5G and 5H). Also, PPARg expression
induced Oct1 and GADD45A (Figure 5G and 5H). To ascertain if
HIF1a-mediated PPARg upregulation led to the induction of
endogenous Oct1 activity, we utilized a luciferase reporter con-
taining synthetic Oct1 response elements (OREs). HIF1a or
PPARg expression induced luciferase reporter activity in an
ORE-dependent manner. Depletion of PPARg inhibited HIF1a-
mediated induction of reporter activity (Figure 5I). Furthermore,
using GADD45A promoter-luciferase reporter constructs as
readout for Oct1 activity, we demonstrate also that GADD45A
promoter activation in response to either HIF1a or PPARg occurs
in an ORE-dependent manner (Figure 5J). Importantly, depletion
of either Oct1 or GADD45A in NMCs suppressed PPARg-medi-
ated caspase 3 activation (Figure 5K). Knockdown of GADD45A
also reduced the extent of PPARg-mediated apoptosis as
assayed by TUNEL staining (Figure S10C). Together, these find-
ings suggest the existence of a HIF1a-PPARg-Oct1-GADD45A
pathway involved in the generation of cleaved caspase 3, leading
to an induction of cardiomyocyte apoptosis.
Inhibition of HIF1a Protects from Hypertrophy-Induced
Cardiac Dysfunction
The protection from hypertrophic stress-induced TAG accumula-
tion and apoptosis conferred by the absence of HIF1a raised the
possibility that HIF1a deficiency may lead to improved cardiac
function. 1K1C or TAC induced pronounced hypertrophy in
Hif1a fl/fl but not Hif1a cKO mice (Figures 6A and S11A). Resis-
tance to hypertrophy induction by either TAC or ISO infusion
was also observed in mice systemically heterozygous for Hif1a
(Hif1a +/) (Figures S11B and S11C). Cardiac hypertrophy has
been proposed to be a necessary adaptation to pathological
stress by enabling the heart to increase its contractile force
and output. Despite lack of a cardiac hypertrophic response to
TAC in Hif1a cKO or Hif1a +/ mice, cardiac performance
was improved compared to control mice, as evidenced by the
increased fractional shortening and ejection fraction exhibited
byHif1a cKO orHif1a +/ hearts (Table 1, Figures 6B and S11D).
In accord with an increased cardiac performance upon loss
of HIF1a function, several molecular markers indicative of
enhanced performance were upregulated in Hif1a cKO
ventricles, but not in ventricles of Hif1a fl/fl mice, in response to
TAC. These include activation of cAMP response element
binding (CREB), as indicated by the upregulation of Ser133
phosphorylation on CREB, a measure of transcriptionally active
CREB and increased Serca2A expression (Figure 6C). Increased
CREB activity and Serca2A expression promotes cardiac
contractility and has been shown to confer protection from
cardiac dysfunction in response to pathological stress (Muller
et al., 2003), thus supporting the finding that Hif1a deficiencyconfers improved cardiac performance in response to patholog-
ical stress.
DISCUSSION
We propose a molecular mechanism underlying the integration
of glycolysis and lipid anabolism in cardiomyopathy-induced
steatosis involving HIF1a and PPARg. We demonstrate that
pathologic stress induces HIF1a and PPARg and identify the
latter as a HIF1a target gene product. Cardiac HIF1a accumula-
tion is limited to human and mouse models of pathological
hypertrophy and is not observed in physiologic hypertrophy.
HIF1a accumulation in the respective disease models correlated
with increased PPARg expression. PPARg is the principal medi-
ator of TAG anabolism through its transcriptional regulation of
fatty acid uptake (via FAT/CD36), glycerol-3-phosphate genera-
tion (via GPD1), and downstream esterification processes (via
GPAT). These genes are upregulated specifically in diseased
hearts in a HIF1a-dependent manner or upon ablation of Vhlh
function in the absence of any hypertrophic signals. This and
the fact that PPARg is a direct transcriptional target of HIF1a
suggest a mechanism by which pathologic stress-induced
HIF1a accumulation translates into changes in cardiac glucose
and lipid metabolism (Figure 6D).
Stress-mediated activation of the HIF1a-PPARg transcription
axis, while increasing GPAT expression, was accompanied by
a downregulation of M-Cpt1 expression in diseased ventricles.
These changes in gene expression would reinforce a propensity
for lipid anabolism over lipid catabolism in a glycolytically
predominant diseased state. Indeed, diseased and Vhlh-defi-
cient ventricular biopsies were characterized by high levels of
HIF1a, PPARg, and the PPARg target gene products GPD1
and GPAT but lower levels of M-Cpt1 and increased levels of
lipid accumulation. These HIF1a-dependent effects on cardio-
myocyte lipid metabolism were recapitulated in vitro, where
HIF1a led to a considerable inhibition of fatty acid oxidation
concomitant with increased glycolysis-mediated TAG synthesis.
Conversely, the inhibition of HIF1a increased cardiomyocyte fatty
acid oxidation and decreased TAG synthesis, consistent with the
protection from steatosis conferred by the lack of ventricular
HIF1a in vivo when subjected to pathological stress.
HIF1a-dependent development of cardiac steatosis and
progression to heart disease in TAC-induced mice was also char-
acterized by increased apoptosis. Cardiomyocyte apoptosis was
PPARg dependent and involves an established link between
PPARg and the activation of caspase 3 via the Oct1-GADD45A
transcriptional pathway. Thus, it appears that stress-induced acti-
vation of HIF1a coordinately induces, through PPARg, changes in
lipid metabolism by engaging glycerolipid and fatty acid uptake
genes and cell death via the activation of Oct1-GADD45A-depen-
dent caspase 3 cleavage. In this regard, increased myocardialcontained equal amounts of a b-galactosidase expression vector for normalization of luciferase activity (*, c¸, #, and +, p < 0.01). Data are means ± SEM of values
from each group.
(J) GADD45A promoter activity in response to HIF1a and PPARg was determined by transient cotransfection of the WT GADD45A promoter or of a deletion
mutant lacking the ORE, respectively, fused to luciferase and with either an empty vector control or the HIF1aDPro or PPARg expression. All transfections con-
tained equal amounts of a b-galactosidase expression vector for normalization of luciferase activity (*, c¸, #, and %, p < 0.01). Data are means ± SEM of values from
each group.
(K) NMCs were infected with viruses encoding shOct1, shGADD45A, PPARg, or combinations thereof and were probed for Oct1, GADD45A, cleaved caspase 3,
and PPARg. Loading was normalized to sarcomeric a-actinin.Cell Metabolism 9, 512–524, June 3, 2009 ª2009 Elsevier Inc. 521
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and myocardial dysfunction (Son et al., 2007). While these results
suggest a potential mechanism of cardiomyocyte apoptosis
driven by a HIF1a-PPARg axis, they do not rule out that the
reprogramming of cardiac metabolism induced by chronic activa-
Figure 6. Ventricular HIF1a Deficiency
Attenuates Stress-Induced Pathological
Hypertrophy
(A) Hif1a fl/fl and Hif1a cKO mice subjected to TAC
were assessed for development of cardiac hyper-
trophy by heart weight:body weight ratio measure-
ments (* and #, p < 0.05). Data are means ± SEM of
values from eight or ten mice.
(B) Contractile function, expressed as % Frac-
tional Shortening (left) and % Ejection Fraction
(right) of Hif1a fl/fl and Hif1a cKO mice subjected
to sham or TAC surgery, was assessed by echo-
cardiography (* and #, p < 0.05). Data are means ±
SEM of values from eight or ten mice.
(C) Whole-cell lysates of Hif1a fl/fl or Hif1a cKO
ventricles subjected to the sham or TAC protocol
were assessed for HIF1a, PPARg, CREB,
CREBpSer133, and Serca2A levels by immuno-
blotting. Loading was normalized to sarcomeric
a-actinin. Broken lines are used to separate the
respective sets. All samples were run on the
same gel.
(D) Schematic representation of the coregulation
of glycolysis and glycerolipid synthesis by HIF1a.
Hypertrophy-induced HIF1a accumulation is pre-
dicted to simultaneously promote the transcrip-
tional upregulation of glycolytic enzymes and the
direct transcriptional activation of the PPARg
promoter. PPARg activity would lead to the upre-
gulation of its target genes, GPD1 and GPAT,
leading to promotion of glycerolipid biosynthesis,
culminating in TAG accumulation. A secondary
level of coordination is predicted to occur via the
shuttling of NADH and NAD+ between GAPDH
and GPD1. Thus, coordinated regulation of both
these components by HIF1a is hypothesized to
favor cardiomyocyte lipid accumulation in hyper-
trophy.
tion of HIF1a can, in the long term, lead to
depletion of metabolic cofactors neces-
sary to sustain cardiac energetics.
Based on the mechanism proposed,
one might predict a beneficial effect of
HIF1a inactivation in heart disease.
Indeed, loss of HIF1a upon TAC attenu-
ated myocardial hypertrophy, steatosis,
apoptosis, and contractile dysfunction.
The lack of hypertrophy in response to
TAC is consistent with a previous report;
however, our observation of increased
cardiac function and cardiomyocyte
survival in HIF1a-deficient TAC mice
differs from an earlier report (Sano et al.,
2007). The difference in phenotypes
could relate to the fact that, in our model,
HIF1a excision is restricted to ventricular
cardiomyocytes, as opposed to the Cre recombinase line utilized
by Sano et al., where HIF1a is deleted in both the atria and ventri-
cles. Additionally, Sano et al. used a different HIF1a floxed
mouse where Cre recombinase-mediated HIF1a excision results
in the generation of a 107 kDa truncated protein lacking the522 Cell Metabolism 9, 512–524, June 3, 2009 ª2009 Elsevier Inc.
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Regulation of Cardiac Metabolism by a HIF1a-PPARg AxisTable 1. Echocardiography Analysis of Sham and TAC-Induced Hif1a fl/fl and Hif1a cKO Mice
Procedure HIF1a f/f sham HIF1a cKO sham
LVPW (d) 1.98 ± 0.12 1.88 ± 0.05
LVPW (s) 2.28 ± 0.08 2.18 ± 0.03
LVID (d) 3.00 ± 0.10 2.93 ± 0.09
LVID (s) 1.53 ± 0.05 1.40 ± 0.11
IVS (d) 0.30 ± 0.00 0.30 ± 0.00
IVS (s) 0.43 ± 0.05 0.37 ± 0.11
Velocity across ligature (mm/s) 852.61 ± 69.93 712.01 ± 27.52
Procedure HIF1a f/f TAC HIF1a cKO TAC
LVPW (d) 2.17 ± 0.7 1.87 ± 0.03
LVPW (s) 2.50 ± 0.10 2.20 ± 0.06
LVID (d) 3.10 ± 0.06 3.00 ± 0.15
LVID (s) 1.67 ± 0.03 1.27 ± 0.20
IVS (d) 0.33 ± 0.03 0.30 ± 0.06
IVS (s) 0.38 ± 0.03 0.50 ± 0.20
Velocity across ligature (mm/s) 3673.43 ± 126.56 3787.86 ± 207.48
LVPW, left ventricular posterior wall thickness at diastole (d) and systole (s); LVID, left ventricular internal diameter at diastole (d) and systole (s); IVS,
intraventricular septum thickness at diastole (d) and systole (s). Measurements are in millimeter units unless stated otherwise (*, p < 0.05).C-terminal trans-activation domain (Takahashi et al., 2001). This
protein species of HIF1a still contains the N-terminal trans-acti-
vation domain that has been shown to be transcriptionally active
(Ema et al., 1999). Additionally, our observations and interpreta-
tions are supported by the fact that loss of ventricular pVHL func-
tion led to spontaneous hypertrophy, progressing to heart
failure, as observed previously (Lei et al., 2008). Thus, if the
loss of HIF1a or pVHL were to be viewed as loss-of-function
and gain-of-function models, respectively, the phenotypes
described with respect to the loss of HIF1a upon TAC would
be consistent with the view that accumulation of HIF1a is suffi-
cient for pathological hypertrophic development, maintenance,
and progression to failure, while the inhibition of pathological
stress-induced HIF1a accumulation would serve to protect
from the detrimental effects of HIF1a and PPARg on cardiac
metabolism, survival, and function. This view is supported by
the fact that Hif1a +/ mice were similarly protected from
TAC-induced hypertrophy and cardiac dysfunction.
Finally, our data also suggest that pharmacological inhibition
of HIF1a function might have significant therapeutic value in
the prevention or reduction in risk of progression to heart
disease, whereas agonists of PPARg would be predicted to
further accelerate heart disease. Indeed, in mouse studies, the
thiazolidinedione class of selective PPARg agonists, such as
rosiglitazone, pioglitazone, and T-174, has been found to induce
interstitial edema, myocardial ceramide and fatty acid accumu-
lation, cardiomyocyte apoptosis, and eccentric cardiac hyper-
trophy (Arakawa et al., 2004; Baranowski et al., 2007; Duan
et al., 2005). Rosiglitazone and pioglitazone are currently used
to treat diabetes in humans and have, in the clinics, demon-
strated increased incidence of cardiac failure and death (Nissen
and Wolski, 2007). Based on our findings, it is conceivable to
propose that application of PPARg agonists in patients with
subclinical heart disease may exacerbate HIF1a-PPARg-medi-
ated lipid accumulation and apoptosis and progression toward
contractile dysfunction and failure.EXPERIMENTAL PROCEDURES
Animal Breeding and Maintenance
Hif1a fl/fl and Hif1a +/mice were obtained from Randall S. Johnson (Univer-
sity of California, San Diego) and Gregg L. Semenza (Johns Hopkins University
School of Medicine), respectively. VHL fl/fl mice were provided by Rudolf
Jaenisch (Massachusetts Institute of Technology). The MLC2v-cre/+ line
was from Ju Chen (University of California, San Diego). Data presented in
this manuscript represent studies with male mice.
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